Archive

Opinion Published In: May, 2016
FOLFOX4 as First Line Treatment in Advanced Hepatocellular Cancer, when Sorafenib is not Available: Can it be an Option?
Piyush Vyas1*, Marta Dudek1, Ewa Zurawinska Grzelka1, Mateusz Cieslak1, Anna Dryja1 and Seema Vyas2

DOI: 10.19080/CTOIJ.2016.01.555571

Case Report Published In: June, 2016
Blood-Drop Liquid Biopsy for Monitoring Mutation Load and Therapeutic Responses
Nader Javadi1, Andrew Ford2 and Chen-Hsiung Yeh2

DOI: 10.19080/CTOIJ.2016.01.555572

Review Article Published In: June, 2016
The Psychological Aspects of the Treatments Involved in Cancer Quackery: Historical Review
Wilson Onuigbo*

DOI: 10.19080/CTOIJ.2016.01.555573

Research Article Published In: August, 2016
Role of Distal loopogram Before Defunctioning Stoma Reversal- Results From An Indian Tertiary-Care Center
*Girish K Kundagulwar1, Vishwas D Pai1, Supreeta Arya2, Prachi Patil3 and Avanish P Saklani1

DOI: 10.19080/CTOIJ.2016.01.555574

Editorial Published In: August, 2016
Chimeric Antigen Receptor Engineered T (CAR-T) Cells and Cancer Therapy
*Nahla A M Hamed

DOI: 10.19080/CTOIJ.2016.01.555575